Literature DB >> 15262500

Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.

Peter Rusert1, Marek Fischer, Beda Joos, Christine Leemann, Herbert Kuster, Markus Flepp, Sebastian Bonhoeffer, Huldrych F Günthard, Alexandra Trkola.   

Abstract

Methods currently used for HIV-1 viral load measurements are very sensitive, but cannot distinguish between infectious and noninfectious particles. Here we describe the development of a novel, sensitive, and highly reproducible method that allows rapid isolation and quantification of infectious particles from patient plasma. By immobilizing HIV-1 particles in human plasma to platelets using polybrene, we observed a 10- to 1000-fold increase in infectivity over infection protocols using free virus particles. Using this method, we evaluated infectivity in plasma from 52 patients at various disease stages. At plasma viral loads of 1000-10000 HIV-1 RNA copies/ml 18%, at 10,000-50,000 copies/ml 73%, at 50,000-100,000 copies/ml 90%, and above 100,000 copies 96% of cultures were positive. We found that infectious titers among patients vary distinctively but are characteristic for a patient over extended time periods. Furthermore, we demonstrate that by evaluating infectious titers in conjunction with total HIV RNA loads, subtle effects of treatment intervention on viremia levels can be detected. The immobilization procedure does not interfere with viral entry and does not restore the infectivity of neutralized virus. Therefore, this assay system can be utilized to investigate the influence of substances that specifically affect virion infectivity such as neutralizing antibodies, soluble CD4, or protease inhibitors. Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262500     DOI: 10.1016/j.virol.2004.05.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  [HIV, HBV and HCV infected healthcare workers].

Authors:  S Wicker; H F Rabenau
Journal:  Chirurg       Date:  2010-10       Impact factor: 0.955

2.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Authors:  Katie J Doores; Camille Bonomelli; David J Harvey; Snezana Vasiljevic; Raymond A Dwek; Dennis R Burton; Max Crispin; Christopher N Scanlan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets.

Authors:  Chawaree Chaipan; Elizabeth J Soilleux; Peter Simpson; Heike Hofmann; Thomas Gramberg; Andrea Marzi; Martina Geier; Elizabeth A Stewart; Jutta Eisemann; Alexander Steinkasserer; Katsue Suzuki-Inoue; Gemma L Fuller; Andrew C Pearce; Steve P Watson; James A Hoxie; Frederic Baribaud; Stefan Pöhlmann
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

5.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

6.  Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity.

Authors:  Naveen K Vaidya; Ruy M Ribeiro; Christopher J Miller; Alan S Perelson
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

7.  Helical conformation of the SEVI precursor peptide PAP248-286, a dramatic enhancer of HIV infectivity, promotes lipid aggregation and fusion.

Authors:  Jeffrey R Brender; Kevin Hartman; Lindsey M Gottler; Marchello E Cavitt; Daniel W Youngstrom; Ayyalusamy Ramamoorthy
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

8.  TaqMan real-time reverse transcription-PCR and JDVp26 antigen capture enzyme-linked immunosorbent assay to quantify Jembrana disease virus load during the acute phase of in vivo infection.

Authors:  Meredith Stewart; Moira Desport; Nining Hartaningsih; Graham Wilcox
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

9.  Generation of representative primary virus isolates from blood plasma after isolation of HIV-1 with CD44 MicroBeads.

Authors:  Marion Cornelissen; Edwin J Heeregrave; Fokla Zorgdrager; Georgios Pollakis; William A Paxton; Antoinette C van der Kuyl
Journal:  Arch Virol       Date:  2010-09-24       Impact factor: 2.574

10.  Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Authors:  Zoltan Beck; Bruce K Brown; Lindsay Wieczorek; Kristina K Peachman; Gary R Matyas; Victoria R Polonis; Mangala Rao; Carl R Alving
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.